𝔖 Scriptorium
✦   LIBER   ✦

πŸ“

Valuation in Life Sciences: A Practical Guide

✍ Scribed by Boris Bogdan, Ralph Villiger (auth.)


Publisher
Springer-Verlag Berlin Heidelberg
Year
2010
Tongue
English
Leaves
384
Edition
3
Category
Library

⬇  Acquire This Volume

No coin nor oath required. For personal study only.

✦ Synopsis


This book is the first complete guide to valuation in life sciences for industry professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable industry data. After guiding the reader through the theory of valuation, including DCF, decision trees, and real options, the authors demonstrate how to value projects, patents, licences, firms, and stocks on real-life examples, even treating complex licence and company structures. Special emphasis is put on the practicability of the proposed methods by including many hands-on examples, without compromising on realistic results.

The 3rd edition of the successful work includes new studies about success rates and about drug development in the biotech industry and their influence on valuation.

✦ Table of Contents


Front Matter....Pages i-xiii
Introduction....Pages 1-9
Basics of Valuation....Pages 11-65
Valuation in Life Sciences....Pages 67-303
Exercises....Pages 305-329
Case Studies....Pages 331-361
Back Matter....Pages 363-370

✦ Subjects


Finance /Banking; Computer Appl. in Life Sciences; Health Informatics; Pharmacy; Biotechnology; Management/Business for Professionals


πŸ“œ SIMILAR VOLUMES


Valuation in Life Sciences: A Practical
✍ Bogdan B., Villiger R. πŸ“‚ Library πŸ“… 2007 🌐 English

This book is the first complete guide to valuation in life sciences for industry professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable indu

Valuation in Life Sciences: A Practical
✍ Boris Bogdan, Ralph Villiger πŸ“‚ Library πŸ“… 2008 πŸ› Springer 🌐 English

<P>This book is the first complete guide to valuation in life sciences for industryΒ  professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable

Valuation in Life Sciences: A Practical
✍ Boris Bogdan, Ralph Villiger πŸ“‚ Library πŸ“… 2007 πŸ› Springer 🌐 English

This book is the first complete guide to valuation in life sciences for industryΒ  professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable ind

Valuation in Life Sciences: A Practical
✍ Dr. Boris Bogdan, Ralph Villiger (auth.) πŸ“‚ Library πŸ“… 2007 πŸ› Springer Berlin Heidelberg 🌐 English

<P>This book is the first complete guide to valuation in life sciences for industry professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable i

Valuation in Life Sciences: A Practical
✍ Dr. Boris Bogdan, Ralph Villiger (auth.) πŸ“‚ Library πŸ“… 2008 πŸ› Springer Berlin Heidelberg 🌐 English

<P>This book is the first complete guide to valuation in life sciences for industry professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable i

Valuation in Life Sciences: A Practical
✍ Boris Bogdan, Ralph Villiger πŸ“‚ Library πŸ“… 2010 πŸ› Springer 🌐 English

<span>Valuation is a hot topic among life sciences professionals. There is no clear understanding on how to use the different valuation approaches and how to determine input parameters. Some do not value at all, arguing that it is not possible to get realistic and objective numbers out of it. Some c